ImmunityBio, Inc. (IBRX)
The price, the headline numbers and the latest news, in one place.
ImmunityBio, Inc. (IBRX) Stock Price, Analysis & Data
No data available
| Bid | 5.7 |
| Market Cap | 8.34B |
| Revenue (ttm) | 166M |
| Net Income (ttm) | -992M |
| 0.12 | |
| -0.95 | |
| n/a | |
| -62.13 | |
| P/B (ttm) | -7.92 |
| P/S (ttm) | 50.31 |
| Earnings Date | Nov 3, 2026 |
| Ask | 10.11 |
| Volume | 6,448,640 |
| Avg. Volume (20D) | 10,462,536 |
| Open | 7.82 |
| Previous Close | 7.95 |
| Day's Range | 7.73 - 7.99 |
| 52-Week Range | 1.95 - 12.43 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated ...
Financial Performance
In 2025, ImmunityBio's revenue was 113.29M, an increase of 668.31% compared to the previous year's 14.75M. Earnings were -351.4M, a decrease of -15.03%.
Financial StatementsEarnings Surprise
- Revenue of $51.24M misses estimates by $0, with 93.91% YoY growth.
- EPS of -0.22 misses estimates by -0.14, with -120.00% YoY decline.
Analysts project revenue of ... Upgrade
3 weeks ago · Simply Wall St.
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On ReturnsImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise questions about how much of the recent progress is a...